The Pharmacy Times® Neurology resource center provides clinical news and articles, information about upcoming conferences and meetings, updated clinical trial listings, and other resources.
What can we help you find?
Riluzole oral film (Exservan, Aquestive Therapeutics) has received early-action approval from the FDA for the treatment of amyotrophic lateral sclerosis.
Approved by the FDA in May 2019, midazolam nasal spray CIV (Nayzilam, UCB) is the first nasal rescue treatment for seizure clusters in the United States.
If approved, risdiplam (Genentech) would be the first at-home administered medicine for patients living with spinal muscular atrophy.
Top news of the day from across the health care landscape.
Officials with the FDA have approved adalimumab-afzb (Abrilada, Pfizer), a biosimilar to Humira, for the treatment of certain patients with rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn disease, ulcerative colitis, and plaque psoriasis.
Cenobamate is an investigational antiepileptic drug that has shown broad spectrum anticonvulsant activity in preclinical studies and seizure models.
Neuromyelitis optica is the fourth chronic disease that hematopoietic stem cell transplantation has appeared to reverse.
Oligodendrocyte progenitor cells were often ignored by scientists studying multiple sclerosis; however, new research shows that they are critical in its production.
Three complement genes identified in a new study may serve as markers for monitoring and predicting the progression and severity of multiple sclerosis.
Patients in a phase 3 study reported better gastrointestinal tolerability with diroximel fumarate (Vumerity) compared with dimethyl fumarate (Tecfidera) in patients with relapsing forms of multiple sclerosis.
Officials with the FDA have approved Allergan’s supplemental Biologics License Application (sBLA) for onabotulinumtoxinA (BOTOX®) to expand its indication to include treatment of pediatric patients, ages 2 to 17 years, with lower limb spasticity, excluding spasticity caused by cerebral palsy.
Kyowa Kirin’s istradefylline (Nourianz) is now available in the United States as adjunctive treatment to levodopa/carbidopa in adult patients with Parkinson’s disease (PD) that are experiencing “off” episodes.